Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels

NCT07043361 · Completed

Last updated 2026-05-28

This clinical trial is testing whether semaglutide helps with weight loss and blood sugar control in people with metabolic disease, and whether their vitamin D levels at the start play a role.

Status Completed The study has finished.

Type Observational

Participants 5,300 people

Who can join Ages 18–80 · all sexes

Timeline Started 2023-12 · est. completion 2025-04

Where 1 site · Israel

What this study is testing ClinicalTrials.gov NCT07043361 ↗

Description as written by the study sponsor.

Objective: Semaglutide, a glucagon-like peptide-1 receptor agonist, is an established therapy for type 2 diabetes (T2D), offering robust glycemic control and weight reduction. Vitamin D has been implicated in metabolic regulation, yet its influence on semaglutide-induced outcomes remains unclear. Research Design and Methods: the investigators conducted a cross-sectional analysis of 5,300 adults with T2D, enrolled in Leumit Health Services, who initiated semaglutide therapy between February 1, 2019, and December 31, 2022. All patients had documented serum 25-hydroxyvitamin D \[25(OH)D\] levels prior to treatment initiation. Metabolic outcomes- including glycemic control (HbA1c), body mass index (BMI), and lipid profile- were assessed at 12 months. Associations between baseline 25(OH)D levels and metabolic changes were evaluated using multivariable regression models, adjusted for demographic and clinical covariates.

Treatments tested

semaglutide Drug

testing the effect of baseline vitamin D on metabolic effects of semaglutide

Main thing measured	relative weight loss measured by BMI
Sponsor	Hillel Yaffe Medical Center
Conditions studied	Metabolic Disease
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07043361 ↗